Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:191
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 50 条
[11]   Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model [J].
Khong, Andrea ;
Brown, Matthew D. ;
Vivian, Justin B. ;
Robinson, Bruce W. S. ;
Currie, Andrew J. .
JOURNAL OF IMMUNOTHERAPY, 2013, 36 (07) :365-372
[12]   Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques [J].
Xianglei Yan ;
Sebastian Ols ;
Rodrigo Arcoverde Cerveira ;
Klara Lenart ;
Fredrika Hellgren ;
Kewei Ye ;
Alberto Cagigi ;
Marcus Buggert ;
Falk Nimmerjahn ;
Jesper Falkesgaard Højen ;
Daniel Parera ;
Ulrich Pessara ;
Stephan Fischer ;
Karin Loré .
Cellular and Molecular Life Sciences, 2023, 80
[13]   Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques [J].
Yan, Xianglei ;
Ols, Sebastian ;
Arcoverde Cerveira, Rodrigo ;
Lenart, Klara ;
Hellgren, Fredrika ;
Ye, Kewei ;
Cagigi, Alberto ;
Buggert, Marcus ;
Nimmerjahn, Falk ;
Hojen, Jesper Falkesgaard ;
Parera, Daniel ;
Pessara, Ulrich ;
Fischer, Stephan ;
Lore, Karin .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (07)
[14]   Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB [J].
Stopforth, Richard J. ;
Cleary, Kirstie L. S. ;
Cragg, Mark S. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 :S88-S94
[15]   A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies [J].
Jian, Cheng-Zhe ;
Lin, Li ;
Hsu, Chia -Lang ;
Chen, Yu-Hsin ;
Hsu, Chiun ;
Tan, Ching -Ting ;
Ou, Da-Liang .
DRUG DISCOVERY TODAY, 2024, 29 (03)
[16]   The engineered agonistic anti-CD40 antibody potentiates the antitumor effects of β-glucan by resetting TAMs [J].
Cheng, Wanpeng ;
Huang, Ziyi ;
Hao, Yongzhe ;
Hua, Hui ;
Zhang, Bo ;
Li, Xiangyang ;
Fu, Fengqing ;
Yang, Jing ;
Zheng, Kuiyang ;
Zhang, Xueguang ;
Qi, Chunjian .
IMMUNOLOGY LETTERS, 2024, 268
[17]   A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia [J].
Furman, Richard R. ;
Forero-Torres, Andres ;
Shustov, Andrei ;
Drachman, Jonathan G. .
LEUKEMIA & LYMPHOMA, 2010, 51 (02) :228-235
[18]   FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells [J].
Carrascosa, Lucia Campos ;
van Beek, Adriaan A. ;
de Ruiter, Valeska ;
Doukas, Michail ;
Wei, Jie ;
Fisher, Timothy S. ;
Ching, Keith ;
Yang, Wenjing ;
van Loon, Karlijn ;
Boor, Patrick P. C. ;
Rakke, Yannick S. ;
Noordam, Lisanne ;
Doornebosch, Pascal ;
Grunhagen, Dirk ;
Verhoef, Kees ;
Polak, Wojciech G. ;
IJzermans, Jan N. M. ;
Ni, Irene ;
Yeung, Yik Andy ;
Salek-Ardakani, Shahram ;
Sprengers, Dave ;
Kwekkeboom, Jaap .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[19]   Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB [J].
Richard J. Stopforth ;
Kirstie L. S. Cleary ;
Mark S. Cragg .
Journal of Clinical Immunology, 2016, 36 :88-94
[20]   Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization [J].
White, Ann L. ;
Dou, Lang ;
Chan, H. T. Claude ;
Field, Vikki L. ;
Mockridge, C. Ian ;
Moss, Kane ;
Williams, Emily L. ;
Booth, Steven G. ;
French, Ruth R. ;
Potter, Elizabeth A. ;
Butts, Cherie ;
Al-Shamkhani, Aymen ;
Cragg, Mark S. ;
Verbeek, J. Sjef ;
Johnson, Peter W. M. ;
Glennie, Martin J. ;
Beers, Stephen A. .
JOURNAL OF IMMUNOLOGY, 2014, 193 (04) :1828-1835